| Literature DB >> 27958743 |
Rachel Saylor Crowley1, Andrew P Riley2, Alexander M Sherwood1, Chad E Groer1, Nirajmohan Shivaperumal3, Miguel Biscaia3, Kelly Paton3, Sebastian Schneider4, Davide Provasi4, Bronwyn M Kivell3, Marta Filizola4, Thomas E Prisinzano1.
Abstract
Opioids are widely used to treat millions suffering from pain, but their analgesic utility is limited due to associated side effects. Herein we report the development and evaluation of a chemical probe exhibiting analgesia and reduced opioid-induced side effects. This compound, kurkinorin (5), is a potent and selective μ-opioid receptor (MOR) agonist (EC50 = 1.2 nM, >8000 μ/κ selectivity). 5 is a biased activator of MOR-induced G-protein signaling over β-arrestin-2 recruitment. Metadynamics simulations of 5's binding to a MOR crystal structure suggest energetically preferred binding modes that differ from crystallographic ligands. In vivo studies with 5 demonstrate centrally mediated antinociception, significantly reduced rewarding effects, tolerance, and sedation. We propose that this novel MOR agonist may represent a valuable tool in distinguishing the pathways involved in MOR-induced analgesia from its side effects.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27958743 PMCID: PMC5189922 DOI: 10.1021/acs.jmedchem.6b01235
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446